Qin et al., 2003 - Google Patents
Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studiesQin et al., 2003
View PDF- Document ID
- 1345407085856777659
- Author
- Qin F
- Impeduglia T
- Schaffer P
- Dardik H
- Publication year
- Publication venue
- Journal of vascular surgery
External Links
Snippet
Objective: Deposition of von Willebrand factor (vWF) is increased in hyperplastic intima of grafts, vWF levels are elevated in patients with cardiovascular diseases, and there is resistance to progression of atherosclerosis in pigs with von Willebrand disease. We …
- 108010047303 von Willebrand Factor 0 title abstract description 106
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qin et al. | Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies | |
Hohenstein et al. | Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and-2 mRNA within the neomembranes of chronic subdural hematoma | |
UA68333C2 (en) | Modified factor vii | |
CA2663547C (en) | Method of treating endothelial dysfunction | |
Mironidou-Tzouveleki et al. | Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus | |
Larsson et al. | Valproic acid selectively increases vascular endothelial tissue‐type plasminogen activator production and reduces thrombus formation in the mouse | |
CN101578376A (en) | Methods of diagnosing and treating an inflammatory response | |
Lundberg et al. | Age-related changes in the signaling and function of vascular smooth muscle cells | |
Wang et al. | Myeloid-related protein-14 regulates deep vein thrombosis | |
Ji et al. | C‐reactive protein induces expression of tissue factor and plasminogen activator inhibitor‐1 and promotes fibrin accumulation in vein grafts | |
Lin et al. | Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti‐nonGal IgG binding to porcine aortic endothelial cells | |
Bustos et al. | Platelet-mediated activation of endothelial cells: implications for the pathogenesis of transplant rejection1 | |
Brommer et al. | Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients | |
Shin et al. | Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis | |
Stirk et al. | Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques | |
Omori et al. | Inhibition of stromal cell–derived factor-1α/CXCR4 signaling restores the blood-retina barrier in pericyte-deficient mouse retinas | |
Shepro et al. | Plasminogen activator activity by cultured bovine aortic endothelial cells | |
Chen et al. | Recombinant human granulocyte colony-stimulating factor enhanced the resolution of venous thrombi | |
CN108076629B (en) | GM-CSF negative regulator for treating, preventing or improving aortic disease | |
US8617538B2 (en) | Mesodermal-like cell population for treating ischemia in mammals | |
Nowak et al. | Thrombolysis with streptokinase in rabbits dose response, fibrin-clot specificity and laboratory evaluation of fibrinolytic effect | |
Jiang et al. | Tumor necrosis factor-α and the early vein graft | |
Rabinovitch | Pathobiology of pulmonary hypertension: impact on clinical management | |
Laura et al. | Thrombin activated Interleukin-1α drives atherogenesis, but also promotes VSMC proliferation and collagen production. | |
Li et al. | Effects of cinnamic acid on expression of tissue factor induced by TNFα in endothelial cells and its mechanisms |